Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell transplantation is very limited.
The current study will evaluate the efficacy of piperacillin/tazobactam compared with imipenem/cilastatin for febrile neutropenia after transplantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| piperacillin/tazobactam | Experimental |
| |
| imipenem/cilastatin | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Piperacillin-tazobactam combination product | Drug | 4.5g q6h, 5-10 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical success rate. | Resolve of clinical symptoms and signs, without change of therapy. | 3 weeks after beginning of empirical therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Microbiologic success rate | Microbiologic success includes eradication, suspected eradication, and super-infection.
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| wenrong huang, Doctor | Employee | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chinese PLA general hospital | Beijing | Beijing Municipality | 100853 | China |
Not provided
| ID | Term |
|---|---|
| D005334 | Fever |
| D009503 | Neutropenia |
| ID | Term |
|---|---|
| D001832 | Body Temperature Changes |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000380 | Agranulocytosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077725 | Piperacillin, Tazobactam Drug Combination |
| D015378 | Imipenem |
| D000077728 | Cilastatin, Imipenem Drug Combination |
| ID | Term |
|---|---|
| D000078142 | Tazobactam |
| D010397 | Penicillanic Acid |
| D010406 | Penicillins |
| D047090 | beta-Lactams |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Imipenem | Drug | 0.5g q6h, 5-10 days |
|
|
| 3 weeks after beginning of empirical therapy |
| Adverse effect | The number of patients developed unexpected medical information at the 3 weeks after beginning of empirical therapy. | 3 weeks after beginning of empirical therapy |
| Cost of drug and therapy | 3 weeks after beginning of empirical therapy |
| D007970 | Leukopenia |
| D000095542 | Cytopenia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007960 | Leukocyte Disorders |
| D007769 |
| Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D010878 | Piperacillin |
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D013457 | Sulfur Compounds |
| D013450 | Sulfones |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
| D013845 | Thienamycins |
| D015780 | Carbapenems |
| D015377 | Cilastatin |
| D003521 | Cyclopropanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D005229 | Fatty Acids, Monounsaturated |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |